Dashboard
Manage Tickers

PCRX Pacira BioSciences, Inc.

Nasdaq pacira.com


$ 22.19 $ 0.81 (3.79 %)    

Monday, 03-Nov-2025 15:59:54 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 624.08 $ 0.00 (0 %)
DIA $ 470.45 $ 0.00 (0 %)
SPY $ 676.73 $ 0.00 (0 %)
TLT $ 89.87 $ 0.00 (0 %)
GLD $ 367.45 $ 0.00 (0 %)
$ 22.19
$ 21.40
$ 19.66 x 50
$ 23.70 x 211
-- - --
$ 16.00 - $ 27.64
1,400,332
na
997.06M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 07-30-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-02-2016 03-31-2016 10-Q
39 02-25-2016 12-31-2015 10-K
40 10-27-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pacira-biosciences-inks-exclusive-worldwide-license-and-collaboration-agreement-with-amacathera--for-amt-143-a-non-opioid-analgesic-ropivacaine-for-postsurgical-pain-control-amacathera-will-receive-an-upfront-payment-of-5m-with-potential-for-milestone-payments-and-sales-based-royalty
Pacira Biosciences Inks Exclusive Worldwid...
11/04/2025 12:15:24

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies ...

pacira-biosciences-presents-updated-three-year-data-on-pcrx-201-gene-therapy-in-patients-with-moderate-to-severe-osteoarthritis-of-the-knee-showing-clinical-improvements-for-up-to-156-weeks-following-single-administration
Pacira BioSciences Presents Updated Three-...
10/28/2025 12:13:54

pacira-biosciences-receives-paragraph-iv-certification-notice-letter-from-qilu-pharmaceutical-qilu-has-filed-abbreviated-new-drug-application-for-product-claiming-to-be-generic-equivalent-of-exparel-pacira-says-intents-to-assert-its-ip-rights
Pacira BioSciences Receives Paragraph IV C...
10/27/2025 12:14:17

pacira-biosciences-to-present-real-world-evidence-evaluating-clinical-effectiveness-and-economic-benefits-of-exparel-at-amcp-nexus-2025-annual-meeting
Pacira BioSciences To Present Real-World E...
10/23/2025 12:02:36

-- Findings Presented at AMCP Nexus 2025 Annual Meeting --BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioScience...

pacira-biosciences-receives-paragraph-iv-notice-letter-for-exparel-from-whiteoak-group-subsidiary-of-zhejiang-haichang
Pacira BioSciences Receives Paragraph IV N...
10/21/2025 12:34:34

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies ...

paccar-posts-downbeat-earnings-joins-neuphoria-therapeutics-citius-pharmaceuticals-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
PACCAR Posts Downbeat Earnings, Joins Neup...
10/21/2025 12:16:10

pacira-biosciences-to-present-new-data-from-phase-1-clinical-trial-evaluating-pcrx-201-gene-therapy-candidate-for-osteoarthritis-of-knee-at-acr-convergence-2025-meeting
Pacira Biosciences To Present New Data Fro...
10/20/2025 20:03:42

pacira-biosciences-narrows-fy2025-sales-guidance-from-725000m-765000m-to-730000m-750000m-vs-739059m-est
Pacira BioSciences Narrows FY2025 Sales Gu...
08/05/2025 20:02:06

Pacira BioSciences (NASDAQ:PCRX) narrows FY2025 sales outlook from $725.000 million-$765.000 million to $730.000 million-$750.0...

pacira-biosciences-q2-adj-eps-074-beats-068-estimate-sales-181099m-miss-183330m-estimate
Pacira BioSciences Q2 Adj. EPS $0.74 Beats...
08/05/2025 20:01:14

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

insights-ahead-pacira-biosciencess-quarterly-earnings
Insights Ahead: Pacira BioSciences's Quart...
08/04/2025 19:08:09

pacira-biosciences-collaborates-with-johnson--johnson-medtech-to-expand-market-reach-of-zilretta-leveraging-early-intervention-sales-force-to-co-promote-treatment-to-existing-and-new-customers
Pacira BioSciences Collaborates With Johns...
07/22/2025 12:03:23

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient accessBRISBA...

pacira-biosciences-announces-reorganization-shuts-down-45-liter-facility-and-reduces-workforce-by-7
Pacira Biosciences Announces Reorganizatio...
07/10/2025 11:39:01

pacira-biosciences-announces-phase-1-data-showing-single-injection-of-gene-therapy-pcrx-201-provides-sustained-pain-stiffness-and-function-improvement-in-knee-osteoarthritis-patients-for-up-to-3-years
Pacira BioSciences Announces Phase 1 Data ...
06/11/2025 12:11:44

-- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years –...

pacira-biosciences-new-preliminary-data-suggests-clinical-immunogenicity-does-not-reduce-sustained-improvements-in-knee-pain-stiffness-and-function-provided-by-gene-therapy-candidate-pcrx-201
Pacira Biosciences: New Preliminary Data S...
05/15/2025 12:13:16

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the saf...

where-pacira-biosciences-stands-with-analysts
Where Pacira BioSciences Stands With Analysts
05/09/2025 13:00:31

needham-maintains-buy-on-pacira-biosciences-lowers-price-target-to-30
Needham Maintains Buy on Pacira BioScience...
05/09/2025 12:47:59

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $32 to...

pacira-biosciences-affirms-fy2025-sales-guidance-of-72500m-76500m-vs-75221m-est
Pacira BioSciences Affirms FY2025 Sales Gu...
05/08/2025 20:01:45

Pacira BioSciences (NASDAQ:PCRX) affirms FY2025 sales outlook from $725.00 million-$765.00 million to $725.00 million-$765.00 m...

pacira-biosciences-q1-adj-eps-062-beats-060-estimate-sales-16892m-miss-17603m-estimate
Pacira BioSciences Q1 Adj. EPS $0.62 Beats...
05/08/2025 20:01:13

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0...

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION